で組織・契約価格をご覧ください。
サイズを選択してください
表示を変更する
この商品について
実験式(ヒル表記法):
C16H16Cl4N2O4S4
CAS番号:
分子量:
570.38
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Assay:
≥95% (HPLC)
Form:
solid
Storage condition:
OK to freeze, protect from light
Quality Segment
assay
≥95% (HPLC)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, protect from light
color
beige to tan
solubility
DMSO: 100 mg/mL
shipped in
ambient
storage temp.
−20°C
SMILES string
[S](=O)(=O)(NCCSSCCN[S](=O)(=O)c2c(ccc(c2)Cl)Cl)c1c(ccc(c1)Cl)Cl
InChI
1S/C16H16Cl4N2O4S4/c17-11-1-3-13(19)15(9-11)29(23,24)21-5-7-27-28-8-6-22-30(25,26)16-10-12(18)2-4-14(16)20/h1-4,9-10,21-22H,5-8H2
InChI key
REQLACDIZMLXIC-UHFFFAOYSA-N
General description
A cell-permeable symmetrical cystamine compound that selectively suppresses cellular HIF-1α, but not HIF-1β, protein synthesis without affecting the transcription of HIF-1α mRNA or the stability of HIF-1α protein. Reduction of cellular HIF-1α by KC7F2 treatment (IC50<20 µM in LN229 cultures under hypoxia condition) is shown to result in decreased transcriptions of HIF-1α-dependent genes, such as CA IX, endothelin 1, enolase 1, and MMP-2. Inhibition of 4EBP1 and S6K phosphorylation, important event for the initiation of protein translation, is also observed in KC7F2 and U87MGD cultures following KC7F2 treatment under hypoxia condition, which may account for, at least in part, the downregulated HIF-1α synthesis.
Packaging
Packaged under inert gas
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Other Notes
Narita, T., et al. 2009. Clin. Cancer Res.15, 6128.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
保管分類
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable
試験成績書(COA)
製品のロット番号・バッチ番号を入力して、試験成績書(COA) を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。